These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 33522964)
1. Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases. Yazu H; Fukagawa K; Shimizu E; Sato Y; Fujishima H Allergy Asthma Clin Immunol; 2021 Feb; 17(1):11. PubMed ID: 33522964 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of topical tacrolimus 0.03% in the management of vernal keratoconjunctivitis: a non-randomized controlled clinical trial. Eltagoury M; Abou Samra W; Ghoneim E Med Hypothesis Discov Innov Ophthalmol; 2022; 11(2):52-63. PubMed ID: 37641784 [TBL] [Abstract][Full Text] [Related]
3. The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis. Yazu H; Shimizu E; Aketa N; Dogru M; Okada N; Fukagawa K; Fujishima H Ann Allergy Asthma Immunol; 2019 Apr; 122(4):387-392.e1. PubMed ID: 30639466 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis. Wan Q; Tang J; Han Y; Wang D; Ye H Ophthalmic Res; 2018; 59(3):126-134. PubMed ID: 28803239 [TBL] [Abstract][Full Text] [Related]
5. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. Ebihara N; Ohashi Y; Uchio E; Okamoto S; Kumagai N; Shoji J; Takamura E; Nakagawa Y; Nanba K; Fukushima A; Fujishima H J Ocul Pharmacol Ther; 2009 Aug; 25(4):365-72. PubMed ID: 19441889 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Clinical Efficacy and Safety of Prolonged Treatment of Vernal and Atopic Keratoconjunctivitis Using Topical Tacrolimus. Hirota A; Shoji J; Inada N; Shiraki Y; Yamagami S Cornea; 2022 Jan; 41(1):23-30. PubMed ID: 34870621 [TBL] [Abstract][Full Text] [Related]
7. Combination of 0.05% Azelastine and 0.1% Tacrolimus Eye Drops in Children With Vernal Keratoconjunctivitis: A Prospective Study. Chen M; Wei A; Ke B; Zou J; Gong L; Wang Y; Zhang C; Xu J; Yin J; Hong J Front Med (Lausanne); 2021; 8():650083. PubMed ID: 34604246 [No Abstract] [Full Text] [Related]
8. The differences of tear function and ocular surface findings in patients with atopic keratoconjunctivitis and vernal keratoconjunctivitis. Hu Y; Matsumoto Y; Dogru M; Okada N; Igarashi A; Fukagawa K; Tsubota K; Fujishima H Allergy; 2007 Aug; 62(8):917-25. PubMed ID: 17620070 [TBL] [Abstract][Full Text] [Related]
11. Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis. Wakamatsu TH; Tanaka M; Satake Y; Dogru M; Fukagawa K; Igarashi A; Fujishima H Mol Vis; 2011 Apr; 17():932-8. PubMed ID: 21541276 [TBL] [Abstract][Full Text] [Related]
12. Conjunctival in vivo confocal scanning laser microscopy in patients with atopic keratoconjunctivitis. Hu Y; Adan ES; Matsumoto Y; Dogru M; Fukagawa K; Takano Y; Tsubota K; Fujishima H Mol Vis; 2007 Aug; 13():1379-89. PubMed ID: 17768384 [TBL] [Abstract][Full Text] [Related]
13. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Vichyanond P; Pacharn P; Pleyer U; Leonardi A Pediatr Allergy Immunol; 2014 Jun; 25(4):314-22. PubMed ID: 24438133 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Safety and Efficacy of Tacrolimus 0.1% in Severe Pediatric Vernal Keratoconjunctivitis. Caputo R; Marziali E; de Libero C; Di Grande L; Danti G; Virgili G; Villani E; Mori F; Bacci GM; Lucenteforte E; Pucci N Cornea; 2021 Nov; 40(11):1395-1401. PubMed ID: 34029239 [TBL] [Abstract][Full Text] [Related]
15. Allergic conjunctivitis: current concepts on pathogenesis and management. Sacchetti M; Abicca I; Bruscolini A; Cavaliere C; Nebbioso M; Lambiase A J Biol Regul Homeost Agents; 2018; 32(1 Suppl. 1):49-60. PubMed ID: 29552874 [TBL] [Abstract][Full Text] [Related]